OCTAVE und OPERA: Missklaenge der Hypertonietherapie? [OCTAVE and OPERA: discordance in hypertension therapy?]

Tools

Item Type:	Article
Title:	OCTAVE und OPERA: Missklaenge der Hypertonietherapie? [OCTAVE and OPERA: discordance in hypertension therapy?]
Creators Name:	Philipp, S., Dietz, R. and Willenbrock, R.
Abstract:	While ACE-inhibitors have proven their prognostic benefit in many hypertension studies, a new approach has been proposed by inhibiting neutral endopeptidase, which degrades natriuretic peptides. The combined inhibition of ACE and endopeptidase was named “vasopeptidase-inhibition” and tested in several trial. Though effective in lowering blood pressure, a superiority to ACE-inhibitors alone could not be shown. A potentially serious side effect was the increased incidence of angioneurotic edema, which led to a complete stop in the development of this pharmaceutical strategy.
Keywords:	Endopeptidase, Vasopeptidase, ACE-inhibition, Bradykinin, Angioneurotic Edema
Source:	Herz
ISSN:	0340-9937
Publisher:	Urban & Vogel
Volume:	29
Number:	3
Page Range:	266-270
Date:	1 May 2004
Official Publication:	https://doi.org/10.1007/s00059-004-2537-9
PubMed:	View item in PubMed

Repository Staff Only: item control page